$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies 원문보기

IPC분류정보
국가/구분 United States(US) Patent 등록
국제특허분류(IPC7판)
  • A61K-039/395
출원번호 US-0044749 (2005-01-27)
등록번호 US7862817 (2010-12-20)
발명자 / 주소
  • Adams, Camellia W.
  • Presta, Leonard G.
  • Sliwkowski, Mark
출원인 / 주소
  • Genentech, Inc.
대리인 / 주소
    Wendy M., Lee
인용정보 피인용 횟수 : 26  인용 특허 : 108

초록

The present application describes humanized anti-ErbB2 antibodies and methods for treating cancer with anti-ErbB2 antibodies, such as humanized anti-ErbB2 antibodies.

대표청구항

What is claimed is: 1. A humanized antibody which binds ErbB2 and blocks ligand activation of an ErbB receptor and comprises the variable light (VL) domain amino acid sequence in SEQ ID NO: 3 and a variable heavy (VH) domain.

이 특허에 인용된 특허 (108)

  1. de Boer Mark (Beverwyle NLX) Conroy Leah B. (Pacifica CA), Anti-CD40 monoclonal antibodies capable of blocking B-cell activation.
  2. Fendly,Brian M., Anti-ErbB2 antibodies.
  3. King C. Richter (Washington DC) Kasprzyk Philip G. (Washington DC) Bird Robert E. (Rockville MD), Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof.
  4. Shawver Laura K. ; Brandis John W. ; Mann Elaina ; Hancock Miriam E. C. ; Mischak Ronald P. ; Monahan John J., Anti-neoplastic drugs in cancer therapy.
  5. Bissery Marie-Christine,FRX, Anti-tumor compositions containing taxane derivatives.
  6. Vandlen Richard L. ; Holmes William E., Antibodies specific for heregulin 2-.alpha..
  7. Senter Peter D. (Seattle WA) Saulnier Mark G. (Middletown CT) Brown Joseph P. (Seattle WA) Kerr David E. (Seattle WA), Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells.
  8. Arakawa Tsutomu ; Kita Yoshiko, Antibody-induced apoptosis.
  9. Tsutomu Arakawa ; Yoshiko Kita, Antibody-induced apoptosis.
  10. Ring David B., Antigen-binding sites of antibody molecules specific for cancer antigens.
  11. Bissery Marie-Christine,FRX, Antitumour compositions containing taxane derivatives.
  12. Plowman Gregory D., Assay for agents active in proliferative disorders.
  13. Ross Jeffrey S. ; Muraca Patrick J., Assessment of prostate cancer.
  14. An Gang ; O'Hara S. Mark ; Ralph David ; Veltri Robert, Biomarkers and targets for diagnosis, prognosis and management of prostate disease.
  15. Capon Daniel J. (Hillsborough CA) Weiss Arthur (Mill Valley CA) Irving Brian A. (San Francisco CA) Roberts Margo R. (San Francisco CA) Zsebo Krisztina (Woodside CA), Chimeric chains for receptor-associated signal transduction pathways.
  16. Greene Mark I. ; Qian Xiaolan, Compositions and methods of treating tumors.
  17. Mark I. Greene ; Donald M. O'Rourke ; Ramachandran Murali ; Byeong-Woo Park, Compositions and methods of treating tumors.
  18. Greene Mark I. (Penn Valley PA) Zhang Xin (Philadelphia PA), Compounds that bind to p185 and methods of using the same.
  19. Huston James S. ; Houston L. L. ; Ring David B. ; Oppermann Hermann, DNA encoding biosynthetic binding protein for cancer marker.
  20. Kraus Matthias H. (Bethesda MD) Aaronson Stuart A. (Vienna VA), DNA segment encoding a gene for a receptor related to the epidermal growth factor receptor.
  21. Carney Walter P. (North Andover MA) McKenzie Sara J. (Lynn MA), Detection and quantification of neu related proteins in the biological fluids of humans.
  22. Carney, Walter P.; McKenzie, Sara J.; Weinberg, Robert A., Detection of neu p185 in cell lysates.
  23. Bargmann Cornelia I. (Arlington MA) Weinberg Robert A. (Brookline MA), Detection of point mutations in neu genes.
  24. Slamon Dennis J. (Woodland Hills CA) McGuire William L. (San Antonio TX), Determination of status in neoplastic disease.
  25. Baughman, Sharon A.; Shak, Steven, Dosages for treatment with anti-ErbB2 antibodies.
  26. Baughman,Sharon A.; Shak,Steven, Dosages for treatment with anti-ErbB2 antibodies.
  27. Akita Robert ; Sliwkowski Mark, ErbB3 antibodies.
  28. Carter Paul J. (San Francisco CA), Expression of functional antibody fragments.
  29. Schaefer Gabriele Maria ; Sliwkowski Mark, Gamma-heregulin.
  30. Jensen Ronald H. ; Cher Michael L., Genetic alterations associated with prostate cancer.
  31. Hudziak Robert Michael ; Shepard H. Michael ; Ullrich Axel, HER2 extracellular domain.
  32. Hudziak Robert Michael ; Shepard H. Michael ; Ullrich Axel,DEX, HER2 extracellular domain.
  33. Marks James D. ; Schier Robert, High affinity human antibodies to tumor antigens.
  34. Marks, James D.; Schier, Robert, High affinity human antibodies to tumor antigens.
  35. Adair,John Robert; Athwal,Diljeet Singh; Emtage,John Spencer, Humanised antibodies.
  36. Adams, Camellia W.; Presta, Leonard G.; Sliwkowski, Mark, Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies.
  37. Sliwkowski, Mark, Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies.
  38. Carter Paul J. ; Presta Leonard G., Humanized antibodies and methods for making them.
  39. Mendelsohn John (La Jolla CA) Kawamoto Tomoyuki (Hiroshima NY JPX) Sato Gordon (Lake Placid NY) Sato J. Denry (Duarte CA), Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor.
  40. Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
  41. Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
  42. Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is a.
  43. Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated.
  44. Carter Paul J. ; Presta Leonard G., Immunoglobulin variants.
  45. Benz Christopher C. ; Papahadjopoulos Demetrios P. ; Park John W. ; Hong Keelung ; Kirpotin Dmitri, Immunoliposomes that optimize internalization into target cells.
  46. Hudziak Robert M. ; Ullrich Axel ; Fendly Brian M., In vivo tumor detection assay.
  47. Kraus Matthias H. (Bethesda MD) Aaronson Stuart A. (Vienna VA), Isolated polypeptide erbB-3, related to the epidermal growth factor receptor and antibody thereto.
  48. Greene Mark I. (Penn Valley PA) Dobashi Kunio (Gunma PA JPX) Davis James G. (Philadelphia PA) Hamuro Junji (Yokahama JPX), Ligand for the neu gene product.
  49. Lippman Marc E. (Bethesda MD) Lupu Ruth (Gaithersburg MD), Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses.
  50. Deborah R. Jaffee ; Kerry J. Flom, Method and kit for the prognostication of breast cancer.
  51. Carter, Paul J.; Presta, Leonard G., Method for making humanized antibodies.
  52. Carter, Paul J.; Presta, Leonard G., Method for making humanized antibodies.
  53. Carter, Paul J.; Presta, Leonard G., Method for making humanized antibodies.
  54. Paul J. Carter ; Leonard G. Presta, Method for making humanized antibodies.
  55. Bacus Sarah S. (Hinsdale IL), Method for prognosticating response to cancer therapy.
  56. Vandlen Richard L. (Hillsborough CA) Holmes William E. (Pacifica CA), Method for purifying heregulin.
  57. Wang Mary Ge ; George ; Jr. Albert Louis ; Light Elizabeth Sophia, Method for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue.
  58. Danenberg, Kathleen D., Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates.
  59. Vandlen Richard L. ; Holmes William E., Method of using HRG2-.alpha. to stimulate P185.sup.HeR2.
  60. Bacus Sarah S. (Hinsdale IL), Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy.
  61. Koski Raymond A., Methods and compositions for determining HER-2/neu expression using monoclonal antibodies.
  62. Cheever Martin A. ; Disis Mary L., Methods for eliciting or enhancing reactivity to HER-2/neu protein.
  63. Curiel David T. ; Deshane Jessy, Methods for modulating protein function in cells using intracellular antibody homologues.
  64. Curiel David T. ; Deshane Jessy, Methods for modulating protein function in cells using, intracellular antibody homologues.
  65. Thorpe Philip E. ; Burrows Francis J., Methods for targeting the vasculature of solid tumors.
  66. Bishop Walter R. ; Brassard Diana L. ; Nagabhushan Tattanahalli L., Methods of inducing cancer cell death and tumor regression.
  67. Greene Mark I., Methods of treating cancerous cells with anti-receptor antibodies.
  68. Erickson,Sharon; Schwall,Ralph; Sliwkowski,Mark; Blattler,Walter, Methods of treatment using anti-ErbB antibody-maytansinoid conjugates.
  69. Frankel Arthur E. (Durham NC) Ring David B. (Redwood City CA) Laird Walter (Pinole CA), Monoclonal anti-human breast cancer antibodies.
  70. Frankel Arthur E. (Palo Alto CA) Ring David B. (Redwood City CA) Bjorn Michael J. (Hercules CA), Monoclonal anti-human breast cancer antibodies.
  71. Hudziak Robert M. (Corvallis OR) Shepard H. Michael (Rancho Santa Fe CA) Ullrich Axel (Portola Valley CA) Fendly Brian M. (Half Moon Bay CA), Monoclonal antibodies directed to the HER2 receptor.
  72. Hudziak Robert M. ; Shepard H. Michael ; Ullrich Axel ; Fendly Brian M., Monoclonal antibodies directed to the HER2 receptor.
  73. Hudziak Robert M. ; Shepard H. Michael ; Ullrich Axel ; Fendly Brian M., Monoclonal antibodies directed to the HER2 receptor.
  74. Hudziak Robert M. ; Shepard H. Michael ; Ullrich Axel ; Fendly Brian M., Monoclonal antibodies directed to the HER2 receptor.
  75. Hudziak Robert M. ; Ullrich Axel ; Fendly Brian M., Monoclonal antibodies directed to the HER2 receptor.
  76. Robert M. Hudziak ; H. Michael Shepard ; Axel Ullrich ; Brian M. Fendly, Monoclonal antibodies directed to the HER2 receptor.
  77. Robert M. Hudziak ; H. Michael Shepard ; Axel Ullrich ; Brian M. Fendly, Monoclonal antibodies directed to the HER2 receptor.
  78. Hudziak Robert M. ; Shepard H. Michael ; Ullrich Axel ; Fendly Brian M., Monoclonal antibodies directed to the her2 receptor.
  79. Vandlen Richard L. ; Holmes William E., Nucleic acids vectors and host cells encoding and expressing heregulin 2-.alpha..
  80. Vandlen Richard L. ; Holmes William E., Nucleic acids, vectors and host cells encoding heregulin.
  81. Andya James ; Cleland Jeffrey L. ; Hsu Chung C. ; Lam Xanthe M. ; Overcashier David E. ; Shire Steven J. ; Yang Janet Yu-Feng ; Wu Sylvia Sau-Yan, Protein formulation.
  82. Andya, James; Cleland, Jeffrey L.; Hsu, Chung C.; Lam, Xanthe M.; Overcashier, David E.; Shire, Steven J.; Yang, Janet Yu-Feng; Wu, Sylvia Sau-Yan, Protein formulation.
  83. Cleland, Jeffrey L.; Hsu, Chung C.; Lam, Xanthe M.; Overcashier, David E.; Yang, Janet Yu-Feng, Protein formulation.
  84. Blank Gregory S., Protein purification.
  85. Blank, Gregory S., Protein purification.
  86. Carol D. Basey ; Greg S. Blank, Protein purification.
  87. Carol D. Basey ; Greg S. Blank, Protein purification.
  88. Carol D. Basey ; Greg S. Blank, Protein purification.
  89. Blank Gregory S., Protein purification by Protein A chromatography.
  90. King C. Richter ; Kraus Matthias H. ; Aaronson Stuart A., Protein related to but distinct from EGF receptor and antibodies reactive therewith.
  91. Slamon Dennis J. ; Press Michael F., Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination.
  92. Wels Winfried S. (Basel CHX) Hynes Nancy E. (Basel CHX) Harweth Ina-Maria (Grenzach-Wyhlen DEX) Groner Bernd (Basel CHX) Hardman Norman (Riehen CHX) Zwickl Markus (Basel CHX), Recombinant antibodies specific for a growth factor receptor.
  93. Wels Winfried Stephan,CHX ; Hynes Nancy E.,CHX ; Harwerth Ina-Maria,DEX ; Groner Bernd,CHX ; Hardman Norman,CHX ; Zwickl Markus,CHX, Recombinant antibodies specific for a growth factor receptor.
  94. Erickson, Sharon; King, Kathleen; Schwall, Ralph, Rodent HER2 tumor model.
  95. Vandlen Richard L. (Hillsborough CA) Holmes William E. (Pacifica CA), Structure, production and use of heregulin.
  96. Anderson Darrell R. ; Hanna Nabil ; Leonard John E. ; Newman Roland A. ; Reff Mitchell E. ; Rastetter William H., Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen.
  97. Deo Yashwant M. ; Goldstein Joel ; Graziano Robert ; Somasundaram Chezian, Therapeutic compounds comprised of anti-Fc receptor antibodies.
  98. Deo Yashwant M. ; Goldstein Joel ; Graziano Robert ; Somasundaram Chezian, Therapeutic compounds comprised of anti-Fc receptor antibodies.
  99. Yashwant M. Deo ; Joel Goldstein ; Robert Graziano ; Chezian Somasundaram, Therapeutic compounds comprised of anti-Fc receptor antibodies.
  100. Deo Yashwant M. ; Graziano Robert ; Keler Tibor, Therapeutic multispecific compounds comprised of anti-Fc.alpha. receptor antibodies.
  101. Andrew J. Dannenberg ; Kotha Subbaramaiah, Treating cancers associated with overexpression of HER-2/neu.
  102. Sliwkowski,Mark X., Treating prostate cancer with anti-ErbB2 antibodies.
  103. Greene Mark I. ; Drebin Jeffrey A., Treatment of tumors with monoclonal antibodies against oncogene antigens.
  104. Adams,Camellia W.; Presta,Leonard G.; Sliwkowski,Mark, Treatment with anti-ErbB2 antibodies and anti-hormonal compounds.
  105. Adams,Camellia W.; Presta,Leonard G.; Sliwkowski,Mark, Treatment with anti-ErbB2 antibodies and chemotherapeutic agents.
  106. Adams,Camellia W.; Presta,Leonard G.; Sliwkowski,Mark, Treatment with anti-ErbB2 antibody combinations.
  107. Vogel Charles L. ; Bellet Robert E., Use of docetaxel for treating cancers.
  108. King C. Richter ; Kraus Matthias H. ; Aaronson Stuart A., erbB-2 gene segments, probes, recombinant DNA and kits for detection.

이 특허를 인용한 특허 (26)

  1. Roschke, Viktor; Lafleur, David; Hilbert, David M.; Kiener, Peter, Ang-2-binding modular recognition domain complexes and pharmaceutical compositions thereof.
  2. Andya, James; Gwee, Shiang C.; Liu, Jun; Shen, Ye, Antibody formulations.
  3. Barbas, III, Carlos F., Antibody targeting through a modular recognition domain.
  4. Weisser, Nina E.; Ng, Gordon Yiu Kon; Wickman, Grant Raymond; Dixit, Surjit Bhimarao; Escobar-Cabrera, Eric; Sanches, Mario, Bispecific antigen-binding constructs targeting HER2.
  5. Harris, Reed J.; Motchnik, Paul A., Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof.
  6. Harris, Reed J.; Motchnik, Paul A., Composition comprising antibody that binds to domain II of HER2 and acidic variants thereof.
  7. Blättler, Walter A.; Chari, Ravi V. J., Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents.
  8. Chari, Ravi V. J.; Blättler, Walter A., Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents.
  9. Barbas, III, Carlos F., EFGR antibodies comprising modular recognition domains.
  10. Roschke, Viktor; Lafleur, David; Hilbert, David M.; Kiener, Peter, EGFR-binding modular recognition domains.
  11. Barbas, III, Carlos F., ERBB2 antibodies comprising modular recognition domains.
  12. Derynck, Mika K.; Kelsey, Stephen M., Extending time to disease progression or survival in cancer patients.
  13. Allison, David E.; Bruno, Rene; Lu, Jian-Feng; Ng, Chee M., Fixed dosing of HER antibodies.
  14. Kao, Yung-Hsiang; Vanderlaan, Martin, HER2 antibody composition.
  15. Chari, Ravi V. J.; Widdison, Wayne C., Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates.
  16. Chari, Ravi; Widdison, Wayne, Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates.
  17. Steeves, Rita M.; Chari, Ravi V. J.; Blattler, Walter A., Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates.
  18. Steeves, Rita M.; Chari, Ravi V. J.; Blattler, Walter A., Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates.
  19. Andya, James; Gwee, Shiang C.; Liu, Jun; Shen, Ye, Method of treating cancer with a pharmaceutical formulation comprising a HER2 antibody.
  20. Blättler, Walter; Chari, Ravi V. J., Methods of treatment using anti-ERBB antibody-maytansinoid conjugates.
  21. Barbas, III, Carlos F., Multispecific antibody targeting and multivalency through modular recognition domains.
  22. Gennaro, Lynn A.; Kao, Yung-Hsiang; Zhang, Yonghua, Pertuzumab variants and evaluation thereof.
  23. Gennaro, Lynn A.; Kao, Yung-Hsiang; Zhang, Yonghua, Pertuzumab variants and evaluation thereof.
  24. Roschke, Viktor; Lafleur, David; Hilbert, David M.; Kiener, Peter, Polynucleotides encoding angiopoietin-2 (ang-2) binding polypeptides.
  25. Amler, Lukas C.; Birkner, Merrill; Lin, Chin-Yu; Moecks, Joachim; Strauss, Andreas, Predicting response to a HER inhibitor.
  26. Barbas, III, Carlos F., VEGF antibodies comprising modular recognition domains.
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로